Traders bought shares of Abbott Laboratories (NYSE:ABT) on weakness during trading hours on Wednesday. $100.81 million flowed into the stock on the tick-up and $34.08 million flowed out of the stock on the tick-down, for a money net flow of $66.73 million into the stock. Of all companies tracked, Abbott Laboratories had the 6th highest net in-flow for the day. Abbott Laboratories traded down ($0.12) for the day and closed at $44.95

Several research firms recently weighed in on ABT. Barclays PLC reissued an “overweight” rating and issued a $48.00 target price on shares of Abbott Laboratories in a research note on Tuesday, July 12th. Jefferies Group reissued a “buy” rating and issued a $44.00 target price on shares of Abbott Laboratories in a research note on Friday, May 13th. Piper Jaffray Cos. cut shares of Abbott Laboratories from an “overweight” rating to a “neutral” rating in a research note on Thursday, April 28th. Credit Suisse Group AG reissued a “buy” rating on shares of Abbott Laboratories in a research note on Saturday, April 30th. Finally, TheStreet downgraded Abbott Laboratories to a “hold” rating in a report on Thursday, May 26th. Eight investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Abbott Laboratories presently has a consensus rating of “Buy” and an average price target of $47.08.

The firm has a market cap of $66.04 billion and a PE ratio of 29.67. The stock’s 50-day moving average price is $41.10 and its 200-day moving average price is $40.08.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, July 20th. The healthcare product maker reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.02. During the same quarter in the previous year, the company posted $0.52 EPS. The firm had revenue of $5.30 billion for the quarter, compared to the consensus estimate of $5.24 billion. The firm’s revenue was up 3.2% compared to the same quarter last year. On average, equities analysts forecast that Abbott Laboratories will post $2.20 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be paid a dividend of $0.26 per share. The ex-dividend date of this dividend is Wednesday, July 13th. This represents a $1.04 annualized dividend and a dividend yield of 2.31%.

In other news, EVP Hubert L. Allen sold 3,400 shares of the stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $37.14, for a total transaction of $126,276.00. Following the completion of the transaction, the executive vice president now owns 91,857 shares in the company, valued at approximately $3,411,568.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stephen R. Fussell sold 41,500 shares of the stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $45.00, for a total value of $1,867,500.00. Following the transaction, the insider now owns 196,467 shares of the company’s stock, valued at approximately $8,841,015. The disclosure for this sale can be found here.

Other hedge funds recently modified their holdings of the company. Dorsey & Whitney Trust CO LLC boosted its stake in shares of Abbott Laboratories by 0.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 30,616 shares of the healthcare product maker’s stock worth $1,377,000 after buying an additional 101 shares during the period. Baldwin Investment Management LLC boosted its stake in shares of Abbott Laboratories by 0.6% in the fourth quarter. Baldwin Investment Management LLC now owns 23,068 shares of the healthcare product maker’s stock worth $1,036,000 after buying an additional 143 shares during the period. Twin Capital Management Inc. boosted its stake in shares of Abbott Laboratories by 0.5% in the fourth quarter. Twin Capital Management Inc. now owns 60,530 shares of the healthcare product maker’s stock worth $2,718,000 after buying an additional 320 shares during the period. Ray Gerald L & Associates Ltd. boosted its stake in shares of Abbott Laboratories by 1.8% in the fourth quarter. Ray Gerald L & Associates Ltd. now owns 27,581 shares of the healthcare product maker’s stock worth $1,238,000 after buying an additional 500 shares during the period. Finally, Mark Sheptoff Financial Planning LLC boosted its stake in shares of Abbott Laboratories by 1.1% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 45,277 shares of the healthcare product maker’s stock worth $2,033,000 after buying an additional 505 shares during the period.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.